Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program

SEATTLE, June 1, 2021 -- (Healthcare Sales & Marketing Network) -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the close of its $10 million financing round. Kineta i... Biopharmaceuticals, Oncology, Venture Capital, Personnel Kineta, anti-VISTA antibody
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news